.jpg)
With such a strong 2019, 2020 was expected to be a ‘mega year’ for life science companies with a reported $1.4 trillion in firepower at their disposal for M&As. However, COVID-19 gave us an unexpected twist.
For this episode of CM Conversations, our Director of Operations Tom Maskill spoke with QIAGEN CEO Thierry Bernard.
For decades, we’ve been talking about how NGS will change the world. But what if NGS was only the start?
Consistent early detection is considered the 'holy grail' of cancer diagnosis. If you can catch cancer early enough, you can stop it developing. Liquid biopsy could be the key to unlocking that potential.
In this episode of CM Conversations, our lab equipment specialist Lucy Smith spoke with Melissa Gammell, Vice President of Business Development at Matphil Technologies about the challenges facing women in biotech.
.jpg)
In this episode, our specialist in the lab equipment space, Lucy Smith, spoke with CEO of Elementar Americas Ryan Titmas. Lucy spoke to Ryan about what it takes to get to the top, as well as some of the lessons he’s learned in his career so far.
As businesses prioritise the wellbeing of their employees, the concept of working a 4 day week is shifting from distant pipedream to reality for a range of organisations around the world.
Even if you’ve been through the process, you may not be aware of exactly what goes into M&A deals. Today, we’ve tried to look into that in a little more detail with Transaction Liability Team Leader Grant Hollis from CFC Underwriting,
When we talk about genomics hubs, then usually we’d be talking about Oxbridge, Boston or Silicon Valley thanks to success stories like 10x Genomics, Illumina or Solexa. However, as the technology needed to conduct genomic R&D becomes more accessible
Coronavirus has provided us with a very large and extremely recent data set for research, patient populations and how different ethnic minorities are being affected versus the research. And the early indicators are that those from minority background
One of the biggest partnering events in the life science calendar Bio-Europe Spring, was scheduled to take place in Paris from March 23 – 27 this year. That all changed with the emergence of COVID-19...
To achieve the WHO's ambitious aim that no woman should die of cervical cancer by 2030 it will take a huge, global effort from companies around the world. Luckily, there is a global community of life sciences companies to help achieve that aim.
.png)
The US remains the largest single-country market in the world for IVD. Here are five companies you need to watch out for.
.png)
While it remains the fourth most common type of cancer for women worldwide, cervical cancer is one of the most preventable and curable with early diagnosis. Let's raise awareness and get more women around the world screened.
NGS has been on a fascinating journey, featuring numerous pioneering players all racing to get their technology to market. A little over 20 years ago, the race began…
Returning from CPhI 2019, in Frankfurt, the words of Eric Langer, President of Bioplan Associates, have stuck with me. Forget the innovation, are biosimilars the real 'workhorse' carrying biopharma to bigger and better things?
A new generation of start-ups are revolutionising cancer diagnosis, detecting disease before patients even show symptoms with liquid biopsy tests. This innovation is rife in the US.
I’ve lost count of the times I’ve seen ‘PhD preferred’, while recruiting for positions in R&D and product development. In the modern life science talent market, are PhDs really so important?
I’ve lost count of the times I’ve seen ‘PhD preferred’, while recruiting for positions in R&D and product development. In the modern life science talent market, are PhDs really so important?
There are countless benefits to companion diagnostics including better evidence of clinical utility & greater patient access, more efficient use of resources, better safety and economic advantages for drug companies.
In today's hyper-connected world, what's the point of conferences? Our Associate Director Jack Shute asked experts from across the speciality chemical space and some of his CM Life Science colleagues to find out.
Product launches and many fascinating, innovative approaches to diagnostics meant that the 71st meeting of the American Association for Clinical Chemistry did not disappoint.
It’s hard to estimate the total size and value of the diagnostics market, however by looking at some of the forecasts available, the scale of the industry is evident.
Cancer doesn’t always make itself known when it presents itself inside a person. People can live with the disease for a long time and, when symptoms manifest, it can be too late as the cancer has become advanced or has spread.
Like the disease itself, cancer treatment and diagnostics comes in many forms. And this number is only increasing as we learn more about the anatomy of the disease and the different ways in which it can be identified.
In 1971 then-US President Richard Nixon famously declared war on drugs, naming drug abuse ‘public enemy number one’. That war’s now been raging for more than 45 years at an estimated cost of over $1 trillion USD.
Everyone is always developing the next big thing in diagnostics. Whether it’s a blood test to identify a disease earlier than ever, or a point-of-care device that might save thousands of lives in a rural area, the whole market is constantly evolving.
Collaborations can produce amazing results. When the Wright Brothers put their heads together, they learned how to fly. When Lennon and McCartney met in 1957, pop music was changed forever.
Globally, nearly 1 in 6 people die from cancer. In 2015 alone, the disease was responsible for 8.8 million deaths – the equivalent of the entire population of London.
In the digital age we live in, information is everything. Facebook make billions through advertising, purely because of the information they collect from us about our habits, searches and interests.
Next Generation Sequencing (NGS) has been the biggest development in biologics since Friedrich Mierscher first found and isolated DNA. The ground breaking technology has given us the ability to truly see what it is that makes us human.
